clinical trial · NCT03393884
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Imunon·phase2·active not recruiting·n = 130
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerIMNN-001CarboplatinPaclitaxel
brief summary
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
started
Sep 5, 2018
primary completion
Jul 25, 2024
completion
Apr 30, 2026
last updated
Apr 13, 2026
official title
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol